US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Targovax announces appointment of Oystein Soug as CEO

Oslo, 2 November, 2016: Targovax ASA ("Targovax" or "the Company"; OSE:TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, today announces that Gunnar Gårdemyr, the Company's Chief Executive Officer, has stepped down.  The Board of Directors has appointed Oystein Soug, currently the Company's Chief Financial Officer, to the role of Chief Executive Officer, effective immediately. The Company has initiated a search for a new Chief Financial Officer. Jónas Einarsson, Chairman of the

Targovax ASA: GRANT OF SHARE OPTIONS

Oslo, 2 November 2016: Reference is made to the announcement made by Targovax ASA ("Targovax" or the "Company") earlier today regarding the appointment of Oystein Soug as the new CEO of the Company. The Board of Directors has resolved to grant 150,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 9.30, to Oystein Soug. Further, the Board will, subject to the resolution by the general meeting of the Company to increase the option pool, at the time of such resolution grant to Oystein Soug the number share options required

Targovax ASA: Completion of subsequent offering, registration of share capital increase

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT Oslo, 17 August 2016: Reference is made to the stock exchange announcement dated 9 August 2016 regarding the result of the subsequent offering of up to 2,666,667 new shares (the "Offer Shares") in Targovax ASA ("Targovax" or the "Company") at a subscription price of NOK 7.50 per Offer Share (the

Targovax ASA: Allocations to primary insiders in the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT Oslo, 9 August 2016: Reference is made to the stock exchange announcement dated 9 August 2016 regarding the final result of the subsequent offering in Targovax ASA ("Targovax" or the "Company"). The following overview sets out the number of new shares allocated to primary insiders in the

Targovax ASA: Result of the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT Oslo, 9 August 2016: Reference is made to the stock exchange announcements dated 8 July 2016 and 11 July 2016 regarding the subsequent offering of up to 2,666,667 new shares (the "Offer Shares") in Targovax ASA ("Targovax" or the "Company") at a subscription price of NOK 7.50 per Offer Share (

Targovax ASA - Last day of the subscription period in the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT Oslo, 8 August 2016: Reference is made to the stock exchange announcements dated 8 July 2016 and 11 July 2016 regarding the subsequent offering of up to 2,666,667 new shares (the "Offer Shares") in Targovax ASA ("Targovax" or the "Company") at a subscription price of NOK 7.50 per share (the "

Anne-Sophie Møller joins Targovax

Targovax has the pleasure of announcing Anne-Sophie Møllers appointment as Director of Clinical Science. Anne-Sophie has an MSc and a PhD in Cell Biology and Immunology, both from the University of Oslo bringing over 25 years of both academic and commercial research experience to Targovax. She joins us from Thermo Fischer Life Technologies where she was the Senior Manager of Method Development & Quality Control. Her academic career includes working at Århus University in Denmark, the University of Oslo and the Norwegian Radium Hospital in addition to over ten years in the pharmaceutical

Targovax ASA - The subscription period in the subsequent offering expires on Monday 8 August at 16:30 CET

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT Oslo, 4 August 2016: Reference is made to the stock exchange announcements dated 8 July 2016 and 11 July 2016 regarding the subsequent offering of up to 2,666,667 new shares (the "Offer Shares") in Targovax ASA ("Targovax" or the "Company") at a subscription price of NOK 7.50 per share (the "

Targovax ASA: Commencement of subscription period for the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTOslo, 11 July 2016: Reference is made to the stock exchange announcements by Targovax ASA ("Targovax" or the "Company") published on 8 July 2016 regarding the subsequent offering of up to 2,666,667 new shares in the Company (the "Subsequent Offering"). The subscription period in the Subsequent

Targovax ASA: Publication of prospectus, listing on Oslo Axess and subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTOslo, 8 July 2016: Reference is made to the stock exchange announcements by Targovax ASA ("Targovax" or the "Company") regarding the contemplated listing of the shares in the Company on Oslo Axess, and the private placement and subsequent offering approved by the extraordinary general meeting of the

Targovax ASA: Completion of private placement, registration of share capital increase

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTOslo, 7 July 2016: Reference is made to the stock exchange notice by Targovax ASA ("Targovax" or the "Company") published on 6 July 2016 regarding the approval by the extraordinary general meeting in the Company of the private placement announced by the Company on 20 June 2016 and 21 June 2016, and

Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTOslo, 6 July 2016: Targovax ASA ("Targovax" or the "Company") has today held an extraordinary general meeting. The general meeting approved all matters on the agenda, including the private placement announced by the Company on 20 June 2016 and 21 June 2016, and the subsequent offer. The

Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma

Oslo 1 July 2016: Targovax today announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin. "New therapies are needed to provide better care for patients with mesothelioma, a highly malignant cancer with poor prognosis" says Dr Magnus Jaderberg, CMO of Targovax. "This clinical trial will provide data to evaluate the efficacy and safety of ONCOS-102 in first and second line mesothelioma patients,

Targovax ASA: Announcement of successful NOK 110 million private placement

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTOslo, 22 June 2016: Reference is made to the announcement from Targovax ASA ("Targovax" or the "Company") dated 20 June 2016 regarding the contemplated private placement to raise NOK 100 - 130 million (the "Private Placement"). Targovax is pleased to announce that the Company's Board of Directors

Targovax ASA: Update on bookbuilding for the private placement of NOK 100 - 130 million

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTTargovax ASA ("Targovax" or the "Company") hereby updates the market on the status of the bookbuilding for the Company's private placement of NOK 100-130 million. Reference is made to the press release from the Company dated 20 June 2016. The Joint Global Coordinators in the private placement

Targovax ASA: Contemplated private placement of NOK 100 - 130 million

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENTOslo, 20 June 2016: Targovax ASA ("Targovax" or the "Company") contemplates to raise NOK 100 - 130 million through a private placement directed towards (i) investors in Norway and internationally  where the minimum subscription and allocation amount is set to the NOK equivalent of EUR 100,000 and (

Magnus Jaderberg, CMO of Targovax, has presented at a symposium by The Royal Swedish Academy of Engineering Sciences

Magnus Jaderberg, Chief Medical Officer at Targovax, held an introductory presentation on immuno-oncology at The Royal Academy of Engineers conference on cancer medicine in Stockholm 16 May 2016. The title of the conference was “Nya cancerläkemedel för individanpassad behandling” (New cancer medicines for individualized treatment). Directed at a general public audience, the various presentations take the viewer step by step in an easy to understand way through the currently ongoing revolution of cancer treatment, which is brought about by new, innovative immuno-oncology medicines. The

Targovax ASA: Registration of share capital increase following exercise of employee options

Reference is made to the notice of 14 April 2016 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee options. The share capital increase has today been registered in the Register of Business Enterprises (NW: Foretaksregisteret). The new registered share capital in the Company is NOK 2,690,536,7 comprising of 26,905,367 shares with a par value of NOK 0.10 per share. For further information please contact: Øystein SougCFOPhone: +47 906 56 525Email: oystein.soug@targovax.com

Exercise of employee share options in Targovax ASA

Reference is made to stock exchange notice of 14 April 2016 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options. As per 29 April 2016, 21,559 shares each with a par value of NOK 0.10 were subscribed by employees, including certain former employees and members of the management of the Company, holding vested options. The new share capital in the Company will accordingly be NOK 2,690,536,7. The share capital increase will be registered in the Register of Business Enterprises (NW: Foretaksregisteret) as soon as practically possible.

Targovax ASA: Grant of restricted stock units to the Board of directors

Reference is made to the minutes from the ordinary general meeting in Targovax ASA (the company) regarding the remuneration to be paid to the board of directors and the implementation of a restricted stock unit (RSU) program for the board of directors. Under the RSU program, the board of directors may choose to receive their remuneration, or parts thereof, in the form of RSUs. The total compensation to each member of the board of directors for both the period 2015-2016 and 2016-2017 have been set out in the minutes from the ordinary general meeting and in the table below. Three of the

Resolution to increase the share capital in Targovax ASA in relation to exercise of employee options

To facilitate the exercise of vested employee options in Targovax ASA (the "Company"), the board of directors of the Company has on 14 April 2016, in accordance with the authorisation granted by the general meeting 14 September 2015, resolved to increase the share capital of up to NOK 59,836.60 by issuance of up to 598,366 new shares, each with a nominal value of NOK 0.10. Depending on the number of vested options exercised, the share capital may be increased from NOK 2,688,380.80 to up to NOK 2,748,217.40. The share capital increase will be registered in the Register of Business

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe